Reply to: “Inconsistent prediction capability of ImmuneCells.Sig across different RNA-seq datasets”
Open Access
- 7 July 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-4
- https://doi.org/10.1038/s41467-021-24304-4
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Hyperprogression under ImmunotherapyInternational Journal of Molecular Sciences, 2019
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanomaNature Medicine, 2018
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy responseNature Medicine, 2018
- Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017
- Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practiceAnnals of Oncology, 2016
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2016
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- Receiver Operating Characteristic Curve in Diagnostic Test AssessmentJournal of Thoracic Oncology, 2010
- A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression dataThe Pharmacogenomics Journal, 2010